CoChat

Targeting telomerase for cancer therapeutics

Open access
Shay, J W, Keith, W N · 2008 · British Journal of Cancer

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604209

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Telomerase gene therapy approaches. Antisense gene therapy such as genetic approaches to target hTERT mRNA, siRNA-mediated inhibition of a component of telomerase and so on, should selectively affect cells that are telomerase positive, while sparing telomerase-negative cells. This would be expected to take a period of time before telomerase-expressing cells died. An approach that may speed up the efficacy of gene therapy involves targeting to all cells a vector that encode an enzyme that when activated by a pro-drug will kill cells. The vector targeting telomerase is combined with an inactive enzyme and when the pro-drug is added, a toxin is released that will only kill cells that are telomerase positive. The oncolytic viral therapy takes advantage of the idea that upregulation or activation of the telomerase gene could enable the replication of a virus that could only replicate if telomerase is present. While this could theoretically affect normal stem like cells expressing telomerase, it is not clear if this will be more toxic that standard chemotherapy that affect all proliferating cells.
Figure 1 Telomerase gene therapy approaches. Antisense gene therapy such as genetic approaches to target hTERT mRNA, siRNA-mediated inhibition of a component of telomerase and so on, should selectively affect cells that are telomerase positive, while sparing telomerase-negative cells. This would be expected to take a period of time before telomerase-expressing cells died. An approach that may speed up the efficacy of gene therapy involves targeting to all cells a vector that encode an enzyme that when activated by a pro-drug will kill cells. The vector targeting telomerase is combined with an inactive enzyme and when the pro-drug is added, a toxin is released that will only kill cells that are telomerase positive. The oncolytic viral therapy takes advantage of the idea that upregulation or activation of the telomerase gene could enable the replication of a virus that could only replicate if telomerase is present. While this could theoretically affect normal stem like cells expressing telomerase, it is not clear if this will be more toxic that standard chemotherapy that affect all proliferating cells.CC BY · PubMed Central
Figure 2 (A) Conventional vs combinatorial therapy. With standard chemotherapy, tumour burden can initially result in a partial tumour reduction response, but almost universally a subset of resistant cells results in recurrence of disease. Thus, standard chemotherapy that does not affect telomere length will results in recurrence of disease with a similar average telomere length (eg, 7 kb). In contrast, combining chemotherapy with telomerase inhibitors should results in both a partial response and a gradual shortening of telomeres (right side of figure). There is every indication on the basis of preclinical research that small oligonucleotide readily enter all cancer cells. The hope is that both sensitive and chemotherapy-resistant cells may shorten their telomeres, eventually leading to more durable responses. (B) Telomerase inhibitors affect stem cells and cancer cell differently. It has been reported (unpublished results) using markers of cancer stem cells that telomeres are shorter compared with normal stem cells. Thus, there should be a window of opportunity to target cancer stem cells with short telomeres using telomerase inhibitors, leading to cancer stem cell depletion before normal stem cells become critically shortened.
Figure 2 (A) Conventional vs combinatorial therapy. With standard chemotherapy, tumour burden can initially result in a partial tumour reduction response, but almost universally a subset of resistant cells results in recurrence of disease. Thus, standard chemotherapy that does not affect telomere length will results in recurrence of disease with a similar average telomere length (eg, 7 kb). In contrast, combining chemotherapy with telomerase inhibitors should results in both a partial response and a gradual shortening of telomeres (right side of figure). There is every indication on the basis of preclinical research that small oligonucleotide readily enter all cancer cells. The hope is that both sensitive and chemotherapy-resistant cells may shorten their telomeres, eventually leading to more durable responses. (B) Telomerase inhibitors affect stem cells and cancer cell differently. It has been reported (unpublished results) using markers of cancer stem cells that telomeres are shorter compared with normal stem cells. Thus, there should be a window of opportunity to target cancer stem cells with short telomeres using telomerase inhibitors, leading to cancer stem cell depletion before normal stem cells become critically shortened.CC BY · PubMed Central
Figure 3 Clinical trial design for telomerase inhibitors. (A) A proposed phase III clinical trial design of telomerase inhibitors as maintenance therapy. This situation may be applicable to small-cell lung cancer after debulking chemotherapy. (B) A proposed phase III clinical trial design of telomerase inhibitors in combination with cytotoxic chemotherapy. The main endpoints are progression-free survival and overall survival.
Figure 3 Clinical trial design for telomerase inhibitors. (A) A proposed phase III clinical trial design of telomerase inhibitors as maintenance therapy. This situation may be applicable to small-cell lung cancer after debulking chemotherapy. (B) A proposed phase III clinical trial design of telomerase inhibitors in combination with cytotoxic chemotherapy. The main endpoints are progression-free survival and overall survival.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 176

Metadata

Authors
Shay, J. W., & Keith, W. N.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Cancer Research UK (GB)
Corresponding author
Shay, J W
Venue
British Journal of Cancer
Published
2008-01-29
Volume
98
Issue
4
Pages
677-683
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2163579602
Cited by
171
References
33
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 6 · 2019: 2 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 7 · 2014: 18 · 2013: 12 · 2012: 14
FWCI
2.35
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
  • Cancer Research UK
  • University of Glasgow
  • National Cancer Institute (P50CA75907, P50CA070907)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
telomerase, cancer therapeutics, telomerase reactivation, cancer stem cells, telomerase regulation, clinical trials, uncontrolled cell proliferation
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Telomerase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting telomerase for cancer therapeutics. https://app.cochat.ai/papers/10.1038/sj.bjc.6604209
The paper
Shay, J. W., & Keith, W. N. (2008). Targeting telomerase for cancer therapeutics. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.